Rigel Pharmaceuticals, Inc.
RIGL
$18.47
-$0.14-0.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 70.30% | 54.84% | 21.65% | 7.48% | -4.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.16% | 54.71% | 21.73% | 7.56% | -4.58% |
| Cost of Revenue | 63.61% | 32.86% | -6.89% | -34.54% | -50.22% |
| Gross Profit | 72.22% | 62.91% | 34.70% | 34.75% | 34.24% |
| SG&A Expenses | 5.51% | 6.92% | -0.61% | -3.48% | -5.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.82% | 12.89% | -2.28% | -12.73% | -20.67% |
| Operating Income | 379.25% | 212.57% | 143.08% | 76.57% | 65.19% |
| Income Before Tax | 292.53% | 173.20% | 115.89% | 62.32% | 55.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 287.75% | 169.69% | 115.89% | 62.32% | 55.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 287.75% | 169.69% | 115.89% | 62.32% | 55.66% |
| EBIT | 379.25% | 212.57% | 143.08% | 76.57% | 65.19% |
| EBITDA | 420.83% | 230.45% | 154.83% | 80.12% | 67.21% |
| EPS Basic | 285.20% | 168.47% | 115.55% | 62.69% | 56.07% |
| Normalized Basic EPS | 280.75% | 169.17% | 114.55% | 66.41% | 56.91% |
| EPS Diluted | 281.67% | 165.94% | 114.90% | 62.87% | 56.27% |
| Normalized Diluted EPS | 278.16% | 167.97% | 114.42% | 66.41% | 56.91% |
| Average Basic Shares Outstanding | 1.22% | 1.05% | 0.97% | 0.95% | 0.88% |
| Average Diluted Shares Outstanding | 2.28% | 1.59% | 1.05% | 0.97% | 0.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |